High-Potency Cannabis Use and Health

 Stephanie Lake, Ph.D., Conor H. Murray, Ph.D., Brittany Henry, B.Sc., Liza Strong, B.Sc., Kendall White, B.Sc., Beau Kilmer, Ph.D., and Ziva D. Cooper, Ph.D.

https://doi.org/10.1176/appi.ajp.20240269

Abstract

Objective:

Amid continuously rising concentrations of delta-9-tetrahydrocannabinol (THC) in cannabis (i.e., potency), high-potency cannabis is a major topic in contemporary cannabis policy discussions, yet its impact on health is not well understood. The authors conducted a systematic review of observational and experimental studies examining the relationship between high-potency cannabis use and a range of health outcomes.

Methods:

Records were obtained from a systematic search of five biomedical research databases. The authors developed ecologically relevant potency (percent THC) exposure-comparison categories (1%–9%, 10%–19%, 20%–30%, kief/resin [∼30%–50%], concentrates [≥60%]) and used a landmark scientific report on cannabis and cannabinoids to determine outcome eligibility. Two reviewers independently conducted article screening and selection, extraction, and quality assessment. Findings were synthesized using both quantitative (association direction, binomial test) and narrative approaches. Certainty in the evidence was determined via the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework.

Results:

Of 4,545 screened records, 42 were eligible. Most studies addressed outcomes in the mental health, “problem” cannabis use, and other substance use domains. Findings in the “problem” cannabis use domain were suggestive of an association with higher-potency cannabis use. Findings were less consistent in other domains but tended to favor poorer outcomes with higher-potency use. Therapeutic outcomes were limited and mixed. Overall, certainty in the evidence was “very low.”

Conclusions:

Findings within the “problem” cannabis use domain were suggestive of an association with high-potency use. Research is largely limited to cross-sectional studies spanning few adverse health domains, underscoring the need for prospective studies probing therapeutic, cardiorespiratory, cancer, and pre- and perinatal outcomes. Policies to curb high-potency cannabis use may be warranted while the evidence base improves.

https://psychiatryonline.org/doi/10.1176/appi.ajp.20240269